Highlighted Text:
Show |
Hide
Full text loading...
Chapter 7 : Mitochondrial Dysfunction and Lactic Acidosis in HIV Disease
Authors:
Ashok Verma1,
Jorge Pardo2
VIEW AFFILIATIONS
HIDE AFFILIATIONS
Affiliations:
1: Department of Neurology, University of Miami Miller School of Medicine, Miami, FL 33136;
2: Department of Neurology, University of Miami Miller School of Medicine, Miami, FL 33136
Content Type: Monograph
Publication Year:
2009
Category: Viruses and Viral Pathogenesis
Book DOI:
10.1128/9781555815691
Chapter DOI:
10.1128/9781555815691.ch7
MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
Preview this chapter:
Mitochondrial Dysfunction and Lactic Acidosis in HIV Disease, Page 1 of 2
< Previous page | Next page > /docserver/preview/fulltext/10.1128/9781555815691/9781555813697_Chap07-1.gif /docserver/preview/fulltext/10.1128/9781555815691/9781555813697_Chap07-2.gif
Abstract:
Mitochondria differ from other subcellular organelles in that they contain their own DNA (mitochondrial DNA [mtDNA]). In mitochondrial disorders, not only does energy failure in tissues and organs result, with a variety of clinical symptoms, but the metabolic block at the end of the anaerobic glycolysis can also lead to excessive pyruvate and lactate accumulation. Lactic acidosis, therefore, can be a manifestation of mitochondrial dysfunction. Symptomatic hyperlactatemia associated with antiretroviral therapy is linked to the mitochondrial respiratory-chain impairment in HIV disease. The recent availability of antiretroviral drugs has substantially reduced HIV-associated mortality and morbidity through decreased viral burden and immune restoration. Mitochondria are the site of generation of most of the cellular ATP pool. The conversion of one molecule of glucose to pyruvate or lactate is associated with the net formation of two molecules of ATP. Nucleoside analog reverse transcriptase inhibitors (NRTI)-related mitochondrial toxicity appears to be the major factor responsible for hyperlactatemia and lactic acidosis in patients with HIV disease. All metabolic acidoses have profound effects on the respiratory, cardiac, and nervous system. It seems essential to discontinue all antiretroviral drugs at the time of NRTI-associated lactic acidosis (NALA) diagnosis; however, surviving patients often need to continue antiretroviral therapy.
Citation:
Verma A, Pardo J.
2009.
Mitochondrial Dysfunction and Lactic Acidosis in HIV Disease,
p 87-93.
In
Goodkin K, Shapshak P, Verma A (ed),
The Spectrum of Neuro-AIDS Disorders.
ASM Press, Washington, DC.
doi: 10.1128/9781555815691.ch7
Key Concept Ranking
- Reverse Transcriptase Inhibitors
- 0.43956658
- Highly Active Antiretroviral Therapy
- 0.42829567
0.43956658
Figures
Mitochondrial Dysfunction and Lactic Acidosis in HIV Disease
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815691.ch07-1,webId=/content/author/10.1128/9781555815691.ch07-1,properties={foaf_givenname=Ashok, foaf_name=Ashok Verma, foaf_surname=Verma, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555815691.ch07-aff1]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815691.ch07-2,webId=/content/author/10.1128/9781555815691.ch07-2,properties={foaf_givenname=Jorge, foaf_name=Jorge Pardo, foaf_surname=Pardo, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555815691.ch07-aff2]]}]]
Citation:
Verma A, Pardo J.
2009.
Mitochondrial Dysfunction and Lactic Acidosis in HIV Disease,
p 87-93.
In
Goodkin K, Shapshak P, Verma A (ed),
The Spectrum of Neuro-AIDS Disorders.
ASM Press, Washington, DC.
doi: 10.1128/9781555815691.ch7
/content/10.1128/9781555815691.ch07.ch07fig01
FIGURE 1.
Mechanism of NRTI-induced mitochondrial toxicity and lactate accumulation. –, inhibition; +, potentiation.
10.1128/9781555815691/ch07fig1_thmb.gif
10.1128/9781555815691/ch07fig1.gif
FIGURE 1.
Mechanism of NRTI-induced mitochondrial toxicity and lactate accumulation. –, inhibition; +, potentiation.
Citation:
Verma A, Pardo J.
2009.
Mitochondrial Dysfunction and Lactic Acidosis in HIV Disease,
p 87-93.
In
Goodkin K, Shapshak P, Verma A (ed),
The Spectrum of Neuro-AIDS Disorders.
ASM Press, Washington, DC.
doi: 10.1128/9781555815691.ch7
/content/10.1128/9781555815691.ch07.ch07fig02
FIGURE 2.
The Cori cycle.
10.1128/9781555815691/ch07fig2_thmb.gif
10.1128/9781555815691/ch07fig2.gif
FIGURE 2.
The Cori cycle.
Citation:
Verma A, Pardo J.
2009.
Mitochondrial Dysfunction and Lactic Acidosis in HIV Disease,
p 87-93.
In
Goodkin K, Shapshak P, Verma A (ed),
The Spectrum of Neuro-AIDS Disorders.
ASM Press, Washington, DC.
doi: 10.1128/9781555815691.ch7
/content/10.1128/9781555815691.ch07.ch07fig03
FIGURE 3.
Management of NRTI-associated hyperlactatemia.
10.1128/9781555815691/ch07fig3_thmb.gif
10.1128/9781555815691/ch07fig3.gif
FIGURE 3.
Management of NRTI-associated hyperlactatemia.
Citation:
Verma A, Pardo J.
2009.
Mitochondrial Dysfunction and Lactic Acidosis in HIV Disease,
p 87-93.
In
Goodkin K, Shapshak P, Verma A (ed),
The Spectrum of Neuro-AIDS Disorders.
ASM Press, Washington, DC.
doi: 10.1128/9781555815691.ch7
References
/content/book/10.1128/9781555815691.ch07
1.
Allaouchiche, B.,, F. Duflo,, L. Cotte,, L. Mathon, and, D. Chassard. 1999. Acute pancreatitis with severe lactic acidosis in an HIV-infected patient on didanosine therapy. J. Antimicrob. Chemother. 44: 137– 138.
2.
Attardi, G.,, and G. Schatz. 1988. Biogenesis of mitochondria. Annu. Rev. Cell Biol. 4: 289– 333.
3.
Brinkman, K. 2001. Management of hyperlactatemia: no need for routine lactate measurements. AIDS 15: 795– 797.
4.
Brinkman, K.,, H. ter Hofstede,, D. Burger,, J. Smeitink, and, P. Koopmans. 1998. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 12: 1735– 1744.
5.
Brinkman, K.,, J. Smeitink,, J. Romijn, and, P. Reiss. 1999. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354: 1112– 1115.
6.
Brinkman, K.,, S. Vrouenraets,, R. Kauffmann,, H. Weigel, and, J. Frissen. 2000. Treatment of nucleoside reverse transcriptase inhibitor-induced lactic acidosis. AIDS 14: 2801– 2802.
7.
Carpenter, C.,, D. Cooper,, M. Fischl,, J. Gatell,, B. Gazzard,, S. Hammer,, M. Hirsch,, D. Jacobsen,, D. Katzenstein,, J. Montaner,, D. Richman,, M. Saag,, M. Schechter,, R. Schooley,, M. Thompson,, S. Vella,, P. Yeni, and, P. Volberding. 2000. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 283: 381– 390.
8.
Carr, A.,, J. Miller,, M. Law, and, D. Cooper. 2000. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14: F25– F32.
9.
Chariot, P.,, I. Drogou,, I. de Lacroix-Szmania,, M. C. Eliezer-Vanerot,, B. Chazaud,, A. Lombès,, A. Schaeffer, and, E. S. Zafrani. 2000. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J. Hepatol. 30: 156– 160.
10.
Cihlar, T.,, and M. Chen. 1996. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol. Pharmacol. 50: 1502– 1510.
11.
Cĉté, H. C.,, Z. L. Brumme,, K. J. Craib,, C. S. Alexander,, B. Wynhoven,, L. Ting,, H. Wong,, M. Harris,, P. R. Harrigan,, M. V. O’Shaughnessy, and, J. S. Montaner. 2002. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N. Engl. J. Med. 346: 811– 820.
12.
Dalton, S.,, and A. Rahimi. 2001. Emerging role of riboflavin in the treatment of nucleoside analogue induced type B lactic acidosis. AIDS Patient Care STDS 15: 611– 614.
13.
Delgado, J.,, M. Harris,, A. Tesiorowski, and, J. Montaner. 2001. Symptomatic elevations of lactic acid and their response to treatment manipulation in human immunodeficiency virus-infected persons: a case series. Clin. Infect. Dis. 33: 2072– 2074.
14.
de Mendoza, C.,, and V. Soriano. 2005. The role of hepatitis C virus (HCV) in mitochondrial DNA damage in HIV/HCV-coinfected individuals. Antivir. Ther. 10: M109– M115.
15.
DeStefano, N.,, P. Mathews,, B. Ford,, A. Genge,, G. Karpati, and, D. Arnold. 1995. Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. Neurology 45: 1193– 1198.
16.
DiMauro, S.,, E. Bonilla,, M. Davidson,, M. Hirano, and, E. Scchon. 1998. Mitochondria in neuromuscular disorders. Biochim. Biophys Acta 1366: 199– 210.
17.
Falco, V.,, R. Rodrigues,, E. Ribera,, E. Martinez,, J. Miro,, P. Domingo,, R. Diazarague,, J. Arribas,, J. Gonzalez-Garcia,, F. Montero,, L. Sanchez, and, A. Pahissa. 2002. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of literature. HIV/AIDS 34: 838– 846.
18.
Ferri, K.,, E. Jacotot,, J. Blanco,, J. Este, and, G. Kroeer. 2000. Mitochondrial control of cell death induced by HIV-1-encoded proteins. Ann. N. Y. Acad. Sci. 926: 149– 164.
19.
Fortgang, I.,, P. Belitsos,, R. Chaisson, and, R. Moore. 1995. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am. J. Gastroenterol. 90: 1433– 1436.
20.
Fouty, B.,, F. Frerman, and, R. Reves. 1998. Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet 352: 291– 292.
21.
Gérard, Y.,, L. Maulin,, Y. Yazdanpanah,, X. De La Tribonnière,, C. Amiel,, C. A. Maurage,, S. Robin,, B. Sablonnière,, C. Dhennain, and, Y. Mouton. 2000. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS 14: 2723– 2730.
22.
Giaquinto, C.,, A. De Romeo,, V. Giacomet,, O. Rampon,, E. Ragu,, A. Burlina,, A. De Rossi,, M. Sturkenboom, and, R. D’Elia. 2001. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission. AIDS 15: 1074– 1075.
23.
John, M.,, C. Moore,, I. James,, D. Nolan,, R. Upton,, E. McKinnon, and, S. Mallal. 2001. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 15: 717– 723.
24.
Kakuda, T. 2000. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Ther. 22: 685– 708.
25.
Khouri, S., and H. Cushing. 2000. Lactic acidosis secondary to nucleoside analogue antiretroviral therapy. AIDS Read. 10: 602– 606.
26.
Lenzo, N.,, B. Garas, and, M. French. 1997. Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report. AIDS 11: 1294– 1296.
27.
Lewis, W.,, and M. Dalakas. 1995. Mitochondrial toxicity of antiviral drugs. Nat. Med. 1: 417– 422.
28.
Lim, S.,, and W. Copeland. 2001. Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. J. Biol. Chem. 276: 23616– 23623.
29.
Lonergan, J.,, C. Behling,, H. Pfander,, T. Hassanein, and, W. Mathews. 2000. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin. Infect. Dis. 31: 162– 166.
30.
Lonergan, J.,, R. Barber, and, W. Mathews. 2003. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis. AIDS 17: 2495– 2499.
31.
Mallal, S.,, M. John,, C. Moore,, I. James, and, E. McKinnon. 2000. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 14: 1309– 1316.
32.
Martin, J.,, C. Brown,, N. Matthews-Davis, and, J. Reardon. 1994. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob. Agents Chemother. 38: 2743– 2749.
33.
Medias, M. 1986. Lactic acidosis. Kidney Int. 29: 752– 774.
34.
Miller, K.,, M. Cameron,, L. Wood,, M. Dalakas, and, J. Kovacs. 2000. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann. Intern. Med. 133: 192– 196.
35.
Miró, O.,, S. López,, E. Martínez,, B. Rodríguez-Santiago,, J. L. Blanco,, A. Milinkovic,, J. M. Miró,, V. Nunes,, J. Casademont,, J. M. Gatell, and, F. Cardellach. 2003. Reversible mitochondrial respiratory chain impairment during symptomatic hyperlactatemia associated with antiretroviral therapy. AIDS Res. Hum. Retrovir. 19: 1027– 1032.
36.
Miro, O.,, S. Lopez,, F. Cardellach, and, J. Casademont. 2005. Mitochondrial studies in HAART-related lipodystrophy: from experimental hypothesis to clinical findings. Antivir. Ther. 10: M73– M81.
37.
Moyle, G. 2004. Mitochondrial toxicity: myths and facts. J. HIV Ther. 9: 45– 47.
38.
Napolitano, A.,, S. Salvetti,, M. Vista,, V. Lombardi,, G. Siciliano, and, C. Giraldi. 2000. Long-term treatment with idebenone and riboflavin in a patient with MELAS. Neurol. Sci. 21: S981– S982.
39.
Palella, F. J., Jr.,, K. M. Delaney,, A. C. Moorman,, M. O. Loveless,, J. Fuhrer,, G. A. Satten,, D. J. Aschman,, S. D. Holmberg, et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338: 853– 860.
40.
Pan-Zhou, X.,, L. Cui,, X. Zhou,, J. Sommadossi, and, V. Darley-Usmar. 2000. Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells. Antimicrob. Agents Chemother. 44: 496– 503.
41.
Plymale, D.,, D. Tang,, A. Comardelle,, C. Fermin,, D. Lewis, and, R. Garry. 1999. Both necrosis and apoptosis contribute to HIV-1-induced killing of CD4 cells. AIDS 13: 1827– 1839.
42.
Roge, B.,, J. Calbet,, K. Moller,, H. Ullum,, H. Hendel,, J. Gerstoft, and, B. Pederson. 2000. Mitochondrial function and exercise capacity in HIV infected patients with lipodystrophy, p. 1232. Geneva, Switzerland. XII Int. AIDS Conf.
43.
Sarner, L.,, and A. Fakoya. 2002. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex. Transm. Infect. 78: 58– 59.
44.
Schapira, A. H. 2002. The “new” mitochondrial disorders. J. Neurol. Neurosurg. Psychiatry 72: 144– 149.
45.
Schramm, C.,, R. Wanitschke, and, P. Galle. 1999. Thiamine for the treatment of nucleoside analogue-induced severe lactic acidosis. Eur. J. Anaesthesiol. 16: 733– 735.
46.
Sundar, K.,, M. Suarez,, P. Banogon, and, J. Shapiro. 1997. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. Crit. Care Med. 25: 1425– 1430.
47.
Susin, S.,, N. Zamzami, and, G. Kroemer. 1998. Mitochondria as regulators of apoptosis: doubt no more. Biochim. Biophys. Acta 1366: 151– 165.
48.
Verma, A.,, M. Hirano, and, C. T. Moraes. 2008. Mitochondrial disorders, p. 1785–1798. In W. G. Bradley,, R. B. Daroff,, G. M. Fenichel, and, J. Jankovic (ed.), Neurology in Clinical Practice, 5th ed. Elsevier Butterworth-Heinemann, Philadelphia, PA.
49.
Verma, A.,, R. Schein,, D. Jayaweera, and, D. Kett. 1999. Fulminant neuropathy and lactic acidosis associated with nucleoside analog therapy. Neurology 53: 1365– 1367.